Article

Melanoma and Men: Don't Wait to Get Checked

We see the highest rates of melanoma related mortality in men over the age of 50. Why is this? Often, men are not getting their skin checked on an annual basis, and even when a change occurs it often goes unnoticed. Older males are in a high risk group for melanoma. Hear first-hand experiences and learn why you should schedule a skin exam soon.

https://vimeo.com/126279944

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Image of patient and doctor.
Image of Dr. Doug
Immune Therapy Expands Melanoma Treatment to More Patients
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of a woman with blond hai
Dr. Manisha Thakuria in an interview with CURE
Dr. Beth Goldstein in an interview with CURE
Related Content
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects: © stock.adobe.com.
August 3rd 2025

New Treatment Combo Improves Advanced Melanoma Outcomes

Spencer Feldman
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects.
CURE Cancer Horizons logo
August 3rd 2025

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of man with text..
August 3rd 2025

Key Skin Cancer Treatment Updates From 2025 and What is Still to Come

Ryan Scott
Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for patients with high-risk skin cancer.
Top Cancer Headlines from 2023
August 3rd 2025

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
A A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma: © stock.adobe.com.
August 3rd 2025

Real-World Data Supports Amtagvi’s Benefit in Advanced Melanoma

Spencer Feldman
A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.
TIL therapy is on the rise in melanoma, with potential for other tumor types.
August 3rd 2025

Empowering the Immune System

Darlene Dobkowski, MA
TIL therapy is on the rise in melanoma, with potential for other tumor types.